Emmanuelle Hainaut

TL;DR: This discovery and validation of a balanced and high-potency dual incretin agonist enables a more physiological approach to management of diseases associated with impaired glucose tolerance and represents a new class of drug candidates for the treatment of metabolic diseases.

TL;DR: The unique steroidogenic and hypertensive side effects of torcetrapib may be linked and involve voltage-gated L-type Ca2+ channels, suggesting initially divergent pathways.

TL;DR: Desmin and WT-1 are found as the most sensitive markers for podocyte damage in both acute and chronic glomerular damage followed by vimentin, podocin and synaptopodin.

TL;DR: ZSF1 rats are a promising model for evaluating effects of drugs on cardiac function by echocardiography in the context of metabolic syndrome, and exhibit cardiac hypertrophy, deterioration of diastolic and systolic functions, and increased sensivity to ischemia with age.